| Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia (NCT00455702) | Massachusetts General Hospital | 2004-07-01 |
| A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia (NCT00088621) | Sumitomo Pharma America, Inc. | 2004-07-01 |
| A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone (NCT00796835) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-07-01 |
| Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia (NCT00637234) | University of Cologne | 2004-07-01 |
| A Bioequivalence Study of 15 mg ER OROS Paliperidone (NCT00892489) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-07-01 |
| Aripiprazole in Adolescents With Schizophrenia (NCT00102063) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-07-01 |
| Familial Schizophrenia and Spectrum Personality Disorders (NCT00666146) | University of Maryland, Baltimore | 2004-07-01 |
| Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents (NCT00102479) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-07-01 |
| Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong Chinese (NCT00562926) | Hospital Authority, Hong Kong | 2004-07-01 |
| Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder (NCT00090012) | Eli Lilly and Company | 2004-07-01 |
| Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia (NCT00088478) | Eli Lilly and Company | 2004-06-01 |
| Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women (NCT01041092) | Fundació Sant Joan de Déu | 2004-06-01 |
| A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia (NCT00240708) | Janssen Pharmaceutical K.K. | 2004-06-01 |
| Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia (NCT00085891) | AstraZeneca | 2004-06-01 |
| Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia (NCT00485810) | Eli Lilly and Company | 2004-06-01 |
| 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia (NCT00752427) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-06-01 |
| Cognitive Rehabilitation in Schizophrenia (NCT00248794) | VA Office of Research and Development | 2004-06-01 |
| A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone (NCT00796276) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-05-01 |
| A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia. (NCT00645307) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-05-01 |
| Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis (NCT00396643) | Medical University of Vienna | 2004-05-01 |
| Reducing the Weight of Overweight Schizophrenia Patients (NCT00158366) | University of Pittsburgh | 2004-05-01 |
| A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia (NCT00088634) | Sumitomo Pharma America, Inc. | 2004-05-01 |
| Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia (NCT00086593) | GlaxoSmithKline | 2004-05-01 |
| Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism (NCT01160991) | Central Institute of Mental Health, Mannheim | 2004-05-01 |
| Timing of Voluntary Movement in Patients With Schizophrenia (NCT00080548) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-04-06 |
| Schizophrenia Sensory Gating Deficit With Quetiapine (NCT00536783) | New Mexico VA Healthcare System | 2004-04-01 |
| Seroquel on Glucose Metabolism (NCT00214578) | AstraZeneca | 2004-04-01 |
| A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients (NCT00634348) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-04-01 |
| Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder (NCT00216723) | Korea Otsuka Pharmaceutical Co., Ltd. | 2004-04-01 |
| Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia (NCT00207064) | Birte Glenthoj | 2004-04-01 |
| Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia (NCT00312962) | University of California, San Francisco | 2004-04-01 |
| Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence (NCT00215579) | Duke University | 2004-04-01 |
| Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data? (NCT00223522) | The University of Texas Health Science Center at San Antonio | 2004-04-01 |
| Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia (NCT00083668) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-04-01 |
| The Effects of Nicotine on Cognition in Schizophrenia (NCT00383747) | Massachusetts General Hospital | 2004-04-01 |
| A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function (NCT00791401) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-04-01 |
| Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia (NCT00161031) | University of Maryland, Baltimore | 2004-04-01 |
| Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients (NCT00255918) | University of Colorado, Denver | 2004-03-01 |
| A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers (NCT00892320) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-03-01 |
| L-carnosine for Schizophrenia (NCT00177177) | University of Pittsburgh | 2004-03-01 |
| A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia. (NCT00086320) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-03-01 |
| Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia (NCT00283179) | Taiwan Otsuka Pharm. Co., Ltd | 2004-03-01 |
| Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder (NCT00156715) | Dartmouth-Hitchcock Medical Center | 2004-03-01 |
| Psychiatric Advance Directives for Improved Mental Health Care (NCT00105794) | US Department of Veterans Affairs | 2004-03-01 |
| Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety (NCT00177008) | University of Medicine and Dentistry of New Jersey | 2004-03-01 |
| The Effects of Aripiprazole on Patients With Metabolic Syndrome (NCT00224822) | New Mexico VA Healthcare System | 2004-03-01 |
| Alcohol Use Disorders in Schizophrenia (NCT00280813) | University of Maryland, Baltimore | 2004-03-01 |
| A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia (NCT00650793) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-03-01 |
| Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder (NCT00095524) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-03-01 |
| Energy Homeostasis Under Treatment With Atypical Antipsychotics (NCT00148564) | Charite University, Berlin, Germany | 2004-03-01 |
| Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults. (NCT00758030) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-03-01 |
| Aripiprazole Oral Acceptability Trial (NCT00101569) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-03-01 |
| Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia (NCT00078039) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-03-01 |
| Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients (NCT00176436) | University of Maryland, Baltimore | 2004-02-01 |
| Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism (NCT00287820) | Nathan Kline Institute for Psychiatric Research | 2004-02-01 |
| Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia (NCT00376233) | University of Jena | 2004-02-01 |
| Aripiprazole Treatment of Prodromal Patients (NCT00237874) | Yale University | 2004-02-01 |
| Amisulpride in Schizophrenic Patients (NCT00331981) | Sanofi | 2004-02-01 |
| A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis (NCT00216580) | Janssen Pharmaceutica N.V., Belgium | 2004-02-01 |
| A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305. (NCT00668837) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-02-01 |
| Microglia Activation in Schizophrenia (NCT00205608) | Amsterdam UMC, location VUmc | 2004-01-01 |
| Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes (NCT00108303) | VA Office of Research and Development | 2004-01-01 |
| Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects (NCT00166322) | Ludwig-Maximilians - University of Munich | 2004-01-01 |
| A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia (NCT00210769) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-01-01 |
| Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia (NCT00218231) | National Institute on Drug Abuse (NIDA) | 2004-01-01 |
| Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia (NCT00077714) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-01-01 |
| Galantamine for Cognition in People With Schizophrenia (NCT00320736) | North Suffolk Mental Health Association | 2004-01-01 |
| Assertive Community Treatment in Copenhagen (NCT00225602) | Bispebjerg Hospital | 2004-01-01 |
| Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals With Severe Mental Illness (NCT00078741) | Medical University of South Carolina | 2004-01-01 |
| Efficacy of Pimozide Augmentation for Clozapine Partial Response (NCT00374244) | Yale University | 2004-01-01 |
| Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness (NCT00199940) | Medical College of Wisconsin | 2003-12-01 |
| Folate Supplementation in Schizophrenia (NCT00249288) | Massachusetts General Hospital | 2003-12-01 |
| Identification and Treatment of the Liability to Develop Schizophrenia (NCT00305474) | Central South University | 2003-12-01 |
| A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs (NCT00649064) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-12-01 |
| Comparison of Video Consent Versus Routine Consent for Participation in Research Studies (NCT00430391) | University of California, San Diego | 2003-12-01 |
| A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders (NCT00650611) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-12-01 |
| Treating Schizophrenia by Correcting Abnormal Brain Development (NCT00179465) | Beth Israel Deaconess Medical Center | 2003-11-01 |
| Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia (NCT00080327) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2003-11-01 |
| Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia (NCT00208143) | Creighton University | 2003-11-01 |
| 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients (NCT00159757) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-11-01 |
| A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia (NCT00222794) | University of Pittsburgh | 2003-11-01 |
| New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia (NCT00161018) | University of Maryland, Baltimore | 2003-11-01 |
| The Effects of Risperidone and Olanzapine on Thinking (NCT00108368) | US Department of Veterans Affairs | 2003-10-01 |
| Cognition, Functioning and Quality of Life (NCT00182442) | Hamilton Health Sciences Corporation | 2003-10-01 |
| A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder (NCT00650429) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-10-01 |
| Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia (NCT00088049) | Eli Lilly and Company | 2003-10-01 |
| Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia (NCT00074477) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-10-01 |
| Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects (NCT00328978) | AstraZeneca | 2003-10-01 |
| Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia (NCT01066403) | Heidelberg University | 2003-10-01 |
| Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder (NCT00190749) | Eli Lilly and Company | 2003-10-01 |
| Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) (NCT00212784) | Organon and Co | 2003-09-04 |
| Cognitive Training for Patients With Schizophrenia (NCT01521026) | University of California, San Diego | 2003-09-01 |
| A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia (NCT00573417) | North Suffolk Mental Health Association | 2003-09-01 |
| A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder (NCT00206102) | AstraZeneca | 2003-09-01 |
| Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder (NCT00395031) | Manhattan Psychiatric Center | 2003-09-01 |
| Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment (NCT00337350) | Massachusetts General Hospital | 2003-09-01 |
| A Registry of Treatment Adherence for Patients With Schizophrenia (NCT00283517) | Janssen-Cilag, S.A. | 2003-09-01 |
| Molecular Genetics of Schizophrenia (NCT00006418) | Endeavor Health | 2003-09-01 |
| A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations (NCT00796640) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-09-01 |
| Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder (NCT00100776) | Eli Lilly and Company | 2003-09-01 |